ALK's tablet-based vaccine against grass allergy, GRAZAX®, has been awarded "Product of the Year" by The Confederation of Danish Industry. GRAZAX® is the first allergy tablet to treat the underlying cause of the allergic disease as well as the symptoms. "By developing GRAZAX®, ALK has made an innovative breakthrough, that will pave the way for new tablet-based allergy vaccines," said Jesper Møller, chairman of The Confederation of Danish Industry, when presenting the award. GRAZAX® was launched in Europe in 2007 following a pan-European marketing authorization. Contrary to traditional, symptom-relieving allergy medicine, GRAZAX® treats the actual cause of the allergic disease, and the treatment is administered as a once-daily, fast dissolving tablet. Before the introduction of GRAZAX®, such a registered causal allergy treatment was only available as an injection-based treatment requiring 30-40 visits at specialised allergy clinics. The product award is presented once a year by The Confederation of Danish Industry with a view to honouring companies for developing excellent customer solutions. To be eligible for the product award, the product must have been developed by a Danish company within the past five years, and be exceptionally groundbreaking. "I am truly happy for this important acknowledgement from The Confederation of Danish Industry. Throughout ALK, employees are doing a tremendous job to reach our goal of introducing tablet-based allergy vaccines and thereby offering an actual treatment of the allergic disease to many more patients than today," said Jens Bager, CEO of ALK. For further information, please contact: Jacob Frische, Director, ALK Group Communications, Phone +45 45747551 or +45 22247551